Microvast Holdings announces departure of chief financial officer
On Thursday, Stifel analysts maintained a positive stance on Edwards Lifesciences (NYSE:EW) shares, reiterating a Buy rating and a price target of $90.00. Currently trading at $75.00, the stock shows potential upside according to analyst consensus, with targets ranging from $61.00 to $90.00. InvestingPro data reveals the company maintains a "GOOD" overall financial health score, suggesting solid fundamentals support the positive outlook. The firm’s analysis followed Edwards’ first-quarter earnings call for 2025, which provided an optimistic view of the company’s outlook for the year and the growth potential for its Transcatheter Aortic Valve Replacement (TAVR) product line. The company’s strong market position is reflected in its impressive 79.5% gross profit margin and 8.6% revenue growth over the last twelve months.
Stifel’s commentary highlighted the anticipated advancement in TAVR, particularly noting the expected second-quarter FDA approval for the EARLY TAVR label expansion for asymptomatic patients, a timeline moved up from mid-2025. Edwards Lifesciences’ management expressed readiness to actively market and support this new indication upon receiving FDA clearance.
The firm also pointed out that some physicians have already seen an uptick in patient referrals due to EARLY TAVR, and with the official label, positive feedback from surveyed physicians is likely to increase. This comes as Edwards Lifesciences reported a 5.4% TAVR growth in the first quarter of 2025, which adjusts to 6.5% growth when accounting for year-over-year selling day headwinds.
Looking ahead, Edwards Lifesciences anticipates a TAVR growth rate of approximately 6% over the next three quarters. Stifel views this projection as a solid foundation for the EARLY TAVR initiative to build upon over time, reinforcing the firm’s confidence in the stock’s potential. For deeper insights into Edwards Lifesciences’ growth prospects and valuation metrics, InvestingPro subscribers can access a comprehensive Pro Research Report, part of the platform’s coverage of over 1,400 US stocks.
In other recent news, Edwards Lifesciences reported a robust first quarter for 2025, exceeding earnings and revenue expectations. The company announced earnings per share (EPS) of $0.64, surpassing the projected $0.60, and revenue of $1.41 billion, which also beat the anticipated $1.4 billion. This performance was driven by strong sales in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments. Additionally, Edwards Lifesciences has raised its 2025 sales guidance to a range of $5.7 billion to $6.1 billion, indicating confidence in continued growth. Piper Sandler analysts have upgraded Edwards Lifesciences’ stock from Neutral to Overweight, citing optimism about the company’s growth prospects and strategic positioning. The analysts highlighted the company’s resilience in a challenging macroeconomic environment and its focus on non-deferrable procedures. These developments reflect a positive outlook for Edwards Lifesciences, supported by its strong quarterly performance and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.